Skip to main content

Iovance Biotherapeutics, Inc.

corporate_fare Company Profile

Iovance Biotherapeutics, Inc.

IOVA·NASDAQ·Life Sciences·CIK 0001425205

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treating cancer through tumor infiltrating lymphocyte (TIL) cell therapies. The company aims to be a global leader in innovating, developing, and delivering these therapies for patients with solid tumor cancers. TIL cell therapies work by using an individual's immune system to recognize and destroy cancer cells unique to each patient. These therapies are manufactured using centralized, scalable, and proprietary processes that rejuvenate and multiply each patient's polyclonal T cells into billions. Iovance was founded to expand upon TIL cell therapy initially developed at academic research centers, including the National Cancer Institute (NCI). The company's multi-center trials, scalable manufacturing, regulatory approvals, and commercial infrastructure have made TIL cell therapy a commercially viable treatment accessible to thousands of cancer patients. Iovance's commercial products include Amtagvi® (lifileucel) and Proleukin® (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi® treatment regimen and other applications. Amtagvi® is the first one-time, individualized T cell therapy for a solid tumor cancer, specifically for adult patients with previously treated advanced, unresectable, or metastatic melanoma. It is administered as part of a regimen that includes lymphodepletion and a short course of Proleukin®. Amtagvi® is approved in the U.S. and Canada. The company plans to launch into additional markets with a high prevalence of advanced melanoma, with potential approvals pending in the United Kingdom (UK) and Australia in the first half of 2026, and Switzerland in 2027. In the European Union (EU), Iovance withdrew its initial marketing authorization application (MAA) in July 2025 and is working with the European Medicines Agency (EMA) to resubmit a centralized MAA in 2026.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for IOVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for IOVA spans 10-Q, 8-K, S-3ASR.

Recent high-impact activity:

  • Iovance Q3: Record $121.5M Revenue, Net Loss Narrows to $22.3M, $382.3M Cash
  • Iovance Posts Record $122M Q3 Revenue, 60% Gross Margin; Reiterates $410-420M FY Guidance
  • Iovance Adds Precision TIL Strategy as Enriched Lung Subgroup Hits 59.1% ORR
  • Iovance Slides as Phase 2 Amtagvi NSCLC Data Disappoints
  • Lifileucel Hits 24.6% ORR in NSCLC; Biomarker Subgroup Reaches 59.1%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$263.5M
Net Income
-$390.98M
Diluted EPS
-$1.09
Op. Cash Flow
-$302.41M
Free Cash Flow
-$336.24M
Gross Profit
$90.32M
Operating Income
-$403.36M
Cash & Equivalents
$163.08M
Debt / Equity
0.00×
Net Margin
-148.4%
Shares Outstanding
411.94M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-018899

Short Interest & Short Volume

4.17 days to cover

FINRA reported short interest of 65,189,660 shares in IOVA as of the October 30, 2026 settlement, a 10.6% increase from the prior period — about 4.2 days to cover at its recent average daily volume. On November 20, 2026, 31.6% of IOVA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)65,189,660 shares as of October 30, 2026
Change vs prior period▲ 10.6%
Days to cover4.17 at avg daily volume of 15,639,902
Daily short volume (FINRA facilities)31.6% of 5,834,494 shares on November 20, 2026
5-day average short volume36.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for IOVA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-18.

ATM program1 shelf registration

At-The-Market Offering Extension · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$6.99 +1.25% today
52-week range · as of 2026-11-05 $1.76 – $15.37
Market cap
$3.19B
Volume
13.7M (1.0× avg)
3-mo avg 13.7M
Live data · 2026-11-22 06:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IOVA - Latest Insights

IOVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $6.99 info
Change: -$1.45 (-17%) info
Market Cap: $3.192B info
IOVA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $6.99 info
Change: -$2.25 (-24%) info
Market Cap: $3.192B info
IOVA
Oct 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $6.99 info
Change: -$2.39 (-26%) info
Market Cap: $3.192B info
IOVA
Oct 29, 2026, 3:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $9.69
Real-time Price: $6.99 info
Change: -$2.70 (-28%) info
Market Cap: $3.192B info
IOVA
Oct 29, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.13
Real-time Price: $6.99 info
Change: -$6.14 (-47%) info
Market Cap: $3.192B info
IOVA
Oct 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.30
Real-time Price: $6.99 info
Change: -$7.31 (-51%) info
Market Cap: $3.192B info
IOVA
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.96
Real-time Price: $6.99 info
Change: -$6.97 (-50%) info
Market Cap: $3.192B info
IOVA
Sep 29, 2026, 2:47 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $14.71
Real-time Price: $6.99 info
Change: -$7.72 (-52%) info
Market Cap: $3.192B info
IOVA
Sep 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.25
Real-time Price: $6.99 info
Change: -$4.26 (-38%) info
Market Cap: $3.192B info
IOVA
Sep 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.48
Real-time Price: $6.99 info
Change: -$4.49 (-39%) info
Market Cap: $3.192B info
IOVA
Aug 06, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.19
Real-time Price: $6.99 info
Change: +$0.7962 (+13%) info
Market Cap: $3.192B info
IOVA
Aug 06, 2026, 9:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.72
Real-time Price: $6.99 info
Change: +$1.27 (+22%) info
Market Cap: $3.192B info
IOVA
Aug 06, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.94
Real-time Price: $6.99 info
Change: +$2.05 (+41%) info
Market Cap: $3.192B info
IOVA
Aug 06, 2026, 7:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.00
Real-time Price: $6.99 info
Change: +$1.99 (+40%) info
Market Cap: $3.192B info
IOVA
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.32
Real-time Price: $6.99 info
Change: +$2.67 (+62%) info
Market Cap: $3.192B info
IOVA
Jun 18, 2026, 6:37 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $6.99 info
Change: +$3.08 (+79%) info
Market Cap: $3.192B info
IOVA
Jun 18, 2026, 4:31 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $6.99 info
Change: +$2.99 (+75%) info
Market Cap: $3.192B info
IOVA
Jun 10, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $6.99 info
Change: +$3.19 (+84%) info
Market Cap: $3.192B info
IOVA
Jun 03, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $6.99 info
Change: +$3.11 (+80%) info
Market Cap: $3.192B info
IOVA
Jun 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $6.99 info
Change: +$2.96 (+73%) info
Market Cap: $3.192B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets